Mirum Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company’s lead product candidate, maralixibat, is an investigational oral drug in development for progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome (ALGS).
52 Week High
52 Week Low
Data Provided by Refinitiv. Minimum 15 minutes delayed.
- Five-year transplant-free survival data from the Phase 2 INDIGO study used as the basis for the MAA submission - Maralixibat would be the first treatment labeled for patients with PFIC2 in Europe , if approved FOSTER CITY, Calif. --(BUSINESS WIRE)--Nov. 30, 2020-- Mirum Pharmaceuticals, Inc.
FOSTER CITY, Calif. --(BUSINESS WIRE)--Nov. 23, 2020-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating liver diseases, today announced that the company will participate in the following
- Results of long-term treatment from the ITCH and IMAGINE II studies presented in late-breaking oral presentation at AASLD - Data demonstrates significant and durable improvements in pruritus in children with Alagille syndrome through 220 weeks of maralixibat treatment - Results have been included
Maralixibat data highlights the relationship between the reduction of serum bile acids and pruritus intensity, improved growth, and other quality of life measures. Analysis of the natural variability of pruritus in children with Alagille syndrome demonstrates persistent severity.